|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Enzymotec |
|---|---|
| Information provided by: | Enzymotec |
| ClinicalTrials.gov Identifier: | NCT00736034 |
Purpose
The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment.
This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.
| Condition | Intervention | Phase |
|---|---|---|
|
Memory Impairment |
Dietary Supplement: Phosphatidylserine-Omega3 (SharpPS™-Gold) |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment, Efficacy Study |
| Official Title: | A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment |
| Enrollment: | 18 |
| Study Start Date: | September 2008 |
| Study Completion Date: | April 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 65 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA
EXCLUSION CRITERIA
Contacts and Locations
More Information
| Responsible Party: | Enzymotec ( Inbal Eyal M.Sc ) |
| Study ID Numbers: | SharpPS™-Gold 001 |
| Study First Received: | August 14, 2008 |
| Last Updated: | April 23, 2009 |
| ClinicalTrials.gov Identifier: | NCT00736034 History of Changes |
| Health Authority: | Israel: Ministry of Health |
|
Age Associated Memory Impairment |
|
Signs and Symptoms Nervous System Diseases Neurologic Manifestations Neurobehavioral Manifestations Memory Disorders |